Clinical trial
A Prospective, Randomized, Active-controlled, Double-blind, Parallel, Multi-center, Phase IV, Exploratory Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke
NCT05445895 is registered in ClinicalTrials.gov with SK Chemicals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Randomized, Active-controlled, Double-blind, Parallel, Multi-center, Phase IV, Exploratory Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke
- Lead sponsor
- SK Chemicals Co., Ltd.
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 16, 2022
- Completion date
- November 7, 2025
- Enrollment
- 483 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.